New Releases


Myriad Genetics' Panexia Predictive Pancreatic Cancer Test

The company is planning to develop a new diagnostic test for early detection of pancreatic cancer by combining PALB2 gene mutations with mutations in the BRCA 2 gene and p16 genes, to which Myriad also holds exclusive rights under 10 issued US patents. The test is slated for launch in 2010.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.